Generic dossier
Semaglutide
1.5, 3, 4, 7, 9, 14, 25 mg · Capsule · Antidiabetic
Product data
- Strength
- 1.5, 3, 4, 7, 9, 14, 25 mg
- Dosage form
- Capsule
- Dosage-form group
- Oral solid
- Therapeutic area
- Antidiabetic
- Market
- EU/US
- Status
- Dossier target · Jun 2027
- Development status
- Technology ready; pilot bio planned Oct 2026
- Portfolio
- Generic dossier
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23